



TOMÁS J. ARAGÓN, M.D., Dr.P.H.
Director and State Public Health Officer

State of California—Health and Human Services Agency
California Department of Public Health



GAVIN NEWSOM
Governor

DATE: February 15, 2021

TO: California Local Health Departments

SUBJECT: CDPH COVID-19 Quarantine Guidance for Fully Vaccinated People

On February 10, 2021, CDC updated COVID-19 [quarantine guidance for fully vaccinated people](#). CDPH supports this guidance, which is stated below:

- Vaccinated persons* with an exposure to someone with suspected or confirmed COVID-19 are not required to quarantine if they meet all of the following criteria:
 - Are fully vaccinated (i.e., ≥ 2 weeks following receipt of the second dose in a 2-dose series, or ≥ 2 weeks following receipt of one dose of a single-dose vaccine)
 - Are within 3 months following receipt of the last dose in the series
 - Have remained asymptomatic since the current COVID-19 exposure

Persons who do not meet all 3 of the above criteria should continue to follow current [CDPH quarantine guidance](#) after exposure to someone with suspected or confirmed COVID-19.

Fully vaccinated persons who do not quarantine should still watch for [symptoms of COVID-19](#) for 14 days following an exposure. If they experience symptoms, they should be clinically evaluated for COVID-19, including SARS-CoV-2 testing, if indicated. In addition, they should respond to calls or texts from their local health department and engage in contact tracing efforts if requested to do so.

These criteria could also be applied when considering work restrictions for **fully vaccinated healthcare personnel** with [higher-risk exposures](#), as a strategy to alleviate staffing shortages. Of note, exposed healthcare personnel would not be required to quarantine outside of work.

***Fully vaccinated inpatients and residents in healthcare settings** should continue to follow [CDPH quarantine guidance](#) for healthcare settings following an exposure to someone with suspected or confirmed COVID-19; outpatients should be cared for using appropriate [Transmission-Based Precautions](#).

For more information, see [CDC Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States](#).

